Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
Status:
Recruiting
Trial end date:
2024-03-17
Target enrollment:
Participant gender:
Summary
The overall aim of the study is to demonstrate a clinically meaningful extension of
progression free survival using maintenance pembrolizumab. The aim of the translational
research is to study the immune microenvironment before and during pembrolizumab therapy.